Immunodetection of DAT is vital in dopamine-related research areas such as Parkinson’s disease (PD), schizophrenia, substance use disorder, attention-deficit-hyperactivity disorder (ADHD), depression, and other neuropsychiatric conditions. This evidence concerns the gene SLC6A3 and depressive disorder.